Daunorubicin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Daunorubicin: From Acute Leukaemia to Hodgkin’s Lymphoma
One-Sentence Summary
Daunorubicin is an anthracycline chemotherapy drug, originally used to treat acute lymphoblastic and acute myeloid leukaemia. The TxGNN model predicts it may be effective for Hodgkin’s lymphoma, but the support is limited: 2 related clinical trials (both multi-drug regimens in non-Hodgkin lymphoma) and 20 publications, most of them indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute lymphoblastic leukaemia and acute myeloid leukaemia (including several subtypes). Health Canada indication text is not available in the data compiled for this report. |
| Predicted New Indication | Hodgkin’s lymphoma |
| TxGNN Prediction Score | 0.9981 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold (treat as a research question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II. This is a plausible mechanism against lymphoid malignancies, and its efficacy in acute leukaemia is well established.
Leukaemia and lymphoma are both haematological cancers, and anthracyclines are widely used across them. Two caveats weaken the prediction, however. First, the supporting trials are multi-drug regimens in non-Hodgkin lymphoma, so daunorubicin’s own contribution cannot be isolated. Second, the anthracycline in the standard Hodgkin regimen (ABVD) is doxorubicin, not daunorubicin.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002471 | Phase 2 | Completed | Not reported | Intensive, short-course combination chemotherapy in newly diagnosed poor-risk non-lymphoblastic lymphoma and acute B-lymphoblastic leukaemia, and in recurrent non-Hodgkin lymphoma. Multi-drug regimen, so the daunorubicin effect cannot be isolated. |
| NCT00002691 | Phase 2 | Completed | Not reported | LSA5 protocol of combination chemotherapy in advanced paediatric and adolescent non-Hodgkin lymphoma (stage III/IV). A different lymphoma entity, with daunorubicin as one component. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11699226 | 2001 | Clinical study | Leukemia & Lymphoma | Liposomal daunorubicin in a COP-X regimen in 33 patients with NHL; 81% of evaluable patients responded (88% in aggressive NHL). |
| 9387047 | 1997 | Early clinical evaluation | Investigational New Drugs | Liposomal daunorubicin in 19 patients with relapsed or refractory lymphoma; at the higher dose, one complete and two partial responses, with mild non-haematological toxicity. |
| 11398876 | 2001 | Clinical study | Annals of Oncology | Liposomal daunorubicin in relapsed or refractory NHL (efficacy and toxicity assessment). |
| 12688316 | 2003 | Clinical study | Leukemia & Lymphoma | Liposomal daunorubicin in a PVABEC-type regimen in 35 elderly patients with aggressive NHL. |
| 14584273 | 2003 | Review | Gan to Kagaku Ryoho | Overview of haematologic tumours; ABVD is first-line for advanced Hodgkin lymphoma, with daunorubicin and cytarabine foundational in AML. |
| 10410671 | 1999 | Review | Gan to Kagaku Ryoho | Overview of haematologic tumours and standard regimens, including for advanced Hodgkin lymphoma. |
| 30231396 | 2018 | Review | ASCO Educational Book | Anthracycline-related cardiotoxicity; anthracyclines are a backbone of regimens for leukaemia and Hodgkin lymphoma. |
| 17610809 | 2007 | Systematic review | Health Technology Assessment | Cardioprotection against anthracycline toxicity in children with cancer. |
| 3855571 | 1985 | Clinical study | Scand J Haematol | Intermediate- and high-dose cytarabine with m-AMSA or daunorubicin in relapsed acute leukaemia and lymphoblastic NHL (indirect). |
| 378369 | 1979 | Review | Cancer Treatment Reports | Roles and limitations of daunorubicin and adriamycin in cancer treatment. |
None of these publications is a randomised trial of daunorubicin in Hodgkin lymphoma. The clinical studies concern non-Hodgkin lymphoma.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 01926683 | CERUBIDINE | Not specified | Not specified |
| 02539209 | DAUNORUBICIN HYDROCHLORIDE INJECTION | Not specified | Not specified |
| 02515490 | VYXEOS | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (anthracycline; DNA intercalator and topoisomerase II inhibitor) |
| Myelosuppression Risk | High (anthracyclines commonly cause neutropenia; the model’s contraindication data also flags neutropenia) |
| Emetogenicity Classification | Moderate |
| Monitoring Items | CBC with differential, liver and renal function, cardiac function (e.g. echocardiography or LVEF), uric acid |
| Handling Protection | Must follow cytotoxic drug handling regulations. Please also refer to the package insert warnings and precautions. |
Safety Considerations
- Disease-level contraindication signals (from the knowledge graph, not label text): neutropenia and other severe neutropenic conditions, cardiomyopathy, heart conduction disease, ventricular tachycardia, sudden cardiac arrest, liver disease, kidney disease, gallbladder disease, and infectious disease, including fungal infections.
- Drug Interactions: 100 interactions were identified. Examples:
- Major: cisapride, dolasetron, papaverine, deferiprone, macimorelin.
- Moderate: clarithromycin, levofloxacin, ondansetron, granisetron, palonosetron, famotidine, loperamide, and others.
- Minor: metronidazole.
- Anthracycline cardiotoxicity is a well-recognised class risk, discussed in several of the cited reviews.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but the supporting evidence is indirect. The two trials are multi-drug regimens in non-Hodgkin lymphoma, and the standard Hodgkin regimen uses doxorubicin rather than daunorubicin. Daunorubicin is already marketed in Canada, which lowers access barriers, but this indication is best treated as a research question rather than an action candidate.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data to support the mechanistic link
- Comparative evidence of daunorubicin versus doxorubicin in Hodgkin lymphoma regimens
- A cardiac and haematological safety monitoring plan, given the cumulative anthracycline exposure typical of Hodgkin regimens
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.